CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Purdue Pharma L.P. v. Mylan Pharmaceuticals Inc.

1:15-cv-01155

Overview

Case Number 1:15-cv-01155
Filing Date 2015-12-16
Status Terminated
Termination Date 2017-09-18
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Mylan Pharmaceuticals Inc. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Plaintiff

Purdue Pharma L.P. NPE (University / Research)

Represented By

0 Attorneys Listed
No attorneys available

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 25 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts Counterparts in force
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (25): πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (0 found):

No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.

Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

2 Patents

There are 2 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US9073933
Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
Filed: 2012-02-06
Issued: 2015-07-07
Expired (Term Ended)
Expires: 2026-02-11
US9522919
Oxycodone compositions
Filed: 2015-05-29
Issued: 2016-12-20
Active (8.5 yrs remaining)
Expires: 2035-05-29

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Statutorily Barred

Statutorily Barred β€” Patent expired. Under 35 U.S.C. Β§ 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting truncation noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. 4th & 8th Year Maintenance Fees Paid (12th Year Window Upcoming).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

31

Dispositive

14

Granted

1

Denied

1

Pending / Review

28

Motions by Category

Procedural / Extension Motion 7 Motion to Dismiss (FRCP 12(b)(6)) 8 Claim Construction / Markman Filing 10 Motion to Dismiss 6

Key Dispositive Motions & Rulings

Motion to Dismiss Pending / Under Review
[SEALED] REPLY BRIEF re 106 MOTION to Dismiss for Improper Venue filed by Mylan Pharmaceuticals Inc., Mylan, Inc.. (Phillips, John) (Entered: 08/15/2017)
Entry #122 • 2017-08-15 Document →
Motion to Dismiss Pending / Under Review
REQUEST for Oral Argument by Mylan Pharmaceuticals Inc., Mylan, Inc. re 106 MOTION to Dismiss for Improper Venue . (Phillips, John) (Entered: 08/15/2017)
Entry #123 • 2017-08-15 Document →
Motion to Dismiss Pending / Under Review
[SEALED] ANSWERING BRIEF in Opposition re 106 MOTION to Dismiss for Improper Venue filed by Purdue Pharma L.P., Purdue Pharmaceuticals L.P., Rhodes Technologies...
Entry #118 • 2017-08-08 Document →
Motion to Dismiss Pending / Under Review
MOTION to Dismiss for Improper Venue - filed by Mylan Pharmaceuticals Inc., Mylan, Inc.. (Attachments: # 1 Text of Proposed Order)(Phillips, John) (Entered: 07/...
Entry #106 • 2017-07-25 Document →
Motion to Dismiss Pending / Under Review
[SEALED] OPENING BRIEF in Support re 106 MOTION to Dismiss for Improper Venue filed by Mylan Pharmaceuticals Inc., Mylan, Inc..Answering Brief/Response due date...
Entry #107 • 2017-07-25 Document →
Motion to Dismiss Denied
MEMORANDUM ORDER: The Report and Recommendation (D.I. 67 ) is ADOPTED. The Motion to Dismiss (D.I. 23 ) is DENIED. Signed by Judge Richard G. Andrews on 6/...
Entry #92 • 2017-06-13 Document →

Docket Entries

(141 total)
Pleading / Complaint

COMPLAINT filed against Mylan Pharmaceuticals Inc., Mylan, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1845338.) - filed by Purdue Pharmaceuticals L.P., Purdue Pharma L.P., The P.F. Laboratories, Inc., Rhodes Technologies. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(sec) (Entered: 12/16/2015)

Entry #1 • 2015-12-16
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (sec) (Entered: 12/16/2015)

Entry #2 • 2015-12-16
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 11/3/2015. Date of Expiration of Patent: 3/30/2025.Thirty Month Stay Deadline: 5/3/2018. (sec) (Entered: 12/16/2015)

Entry #3 • 2015-12-16
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,073,933. (sec) (Entered: 12/16/2015)

Entry #4 • 2015-12-16
1

Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Purdue Pharma L.P., Purdue Pharmaceuticals L.P., Rhodes Technologies, The P.F. Laboratories, Inc.. (sec) (Entered: 12/16/2015)

Entry #5 • 2015-12-16
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc